Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Orchard Therapeutics Plc ADR
(NQ:
ORTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
16.52 (1)
Ask (Size)
17.13 (1)
Prev. Close
16.70
Today's Range
N/A - N/A
52wk Range
15.94 - 16.65
Shares Outstanding
184,260,149
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
May 07, 2024
Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
May 03, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Performance
More News
Read More
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
March 20, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics: Q3 Earnings Insights
November 13, 2023
Via
Benzinga
Why Orchard Therapeutics Stock Is Soaring Today
October 05, 2023
Via
The Motley Fool
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
March 18, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
February 05, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
February 02, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
January 25, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
January 24, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
December 11, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
November 30, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
November 28, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
November 13, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
October 26, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
October 24, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Sarepta Therapeutics Stock Showing Rising Relative Strength
October 09, 2023
Via
Investor's Business Daily
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
October 06, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Crude Oil Down 2%; ConAgra Brands Earnings Top Views
October 05, 2023
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
October 05, 2023
Via
Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 05, 2023
Via
Benzinga
Dow Tumbles Over 100 Points; Constellation Brands Raises Profit Forecast
October 05, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Highly Rated Biotech Orchard Therapeutics Scores A Takeover, Shares Nearly Double
October 05, 2023
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
October 05, 2023
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SP® Plus Corporation (Nasdaq - SP), Orchard Therapeutics plc (Nasdaq - ORTX), Summit Materials (NYSE - SUM)
October 05, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.